ArticleBritish journal of cancer2018

Safety and pharmacokinetics of MM-302, a HER2-targeted antibody-liposomal doxorubicin conjugate, in patients with advanced HER2-positive breast cancer: a phase 1 dose-escalation study.

Pamela Munster et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.